PTN Stock: Palatin Technologies, Inc. Stock Price, Analysis & Insights
Get live ptn stock price $10.80, comprehensive Palatin Technologies, Inc. stock analysis, charts, news, and expert forecast. Real-time ptn stock data and investment insights.
Loading chart...
Company Overview
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Company Information
- CEO
- Carl Spana
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
Contact Information
- Website
- https://palatin.com
- Address
- Cedar Brook Corporate Center
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Palatin Technologies, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Carl Spana, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Palatin Technologies, Inc. competes in the Biotechnology within the broader Healthcare. With 280.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange Arca, Palatin Technologies, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Palatin Technologies, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Palatin Technologies, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Palatin Technologies, Inc.
- ⚠Investors should consider how Palatin Technologies, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
280.86M
P/E Ratio
-7.01
Beta
0.94
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 280.86M market capitalization
- Trading Volume: 0 shares traded today
- Price Range: 52-week range of $2.00 - $72.50
- Exchange: Listed on New York Stock Exchange Arca
Financial Metrics
Market Analysis for Palatin Technologies, Inc.
Palatin Technologies, Inc. (PTN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 280.86M, the company represents a significant player in its market. The stock is currently trading at $10.80 with a positivedaily change of 6252.94%.
The company's 30 employee base and presence on the New York Stock Exchange Arcaexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -7.01, beta of 0.94, and 52-week price range from $2.00 to $72.50when evaluating investment opportunities.
Why Invest in Palatin Technologies, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange Arca)
- • Experienced leadership under Carl Spana
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.